RMDA Stock Overview
Produces and sells a range of branded generic pharmaceuticals and nutraceuticals in Egypt.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م2.28 |
| 52 Week High | ج.م3.40 |
| 52 Week Low | ج.م1.31 |
| Beta | 0.21 |
| 11 Month Change | -1.72% |
| 3 Month Change | 2.70% |
| 1 Year Change | 59.97% |
| 33 Year Change | 57.37% |
| 5 Year Change | n/a |
| Change since IPO | 1.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| RMDA | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | -2.1% | -0.6% | 1.4% |
| 1Y | 60.0% | 28.2% | 62.5% |
Return vs Industry: RMDA exceeded the EG Pharmaceuticals industry which returned 28.2% over the past year.
Return vs Market: RMDA underperformed the EG Market which returned 62.5% over the past year.
Price Volatility
| RMDA volatility | |
|---|---|
| RMDA Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in EG Market | 9.0% |
| 10% least volatile stocks in EG Market | 3.3% |
Stable Share Price: RMDA has not had significant price volatility in the past 3 months.
Volatility Over Time: RMDA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Amr Morsy | www.ramedapharma.com |
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals and nutraceuticals in Egypt. It manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use; and diagnostic reagents for individuals, laboratories, and hospitals. The company offers a portfolio of products in various therapeutic areas, such as anti-infective, anti-diabetic, respiratory, ophthalmology, gastrointestinal tract, cardiovascular, central nervous system, vitamins, and analgesics.
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Fundamentals Summary
| RMDA fundamental statistics | |
|---|---|
| Market cap | ج.م3.40b |
| Earnings (TTM) | ج.م213.99m |
| Revenue (TTM) | ج.م1.99b |
15.9x
P/E Ratio1.7x
P/S RatioIs RMDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMDA income statement (TTM) | |
|---|---|
| Revenue | ج.م1.99b |
| Cost of Revenue | ج.م1.06b |
| Gross Profit | ج.م922.92m |
| Other Expenses | ج.م708.93m |
| Earnings | ج.م213.99m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 46.46% |
| Net Profit Margin | 10.77% |
| Debt/Equity Ratio | 59.8% |
How did RMDA perform over the long term?
See historical performance and comparison